Investigators reported that a DNA‑based immunotherapy produced substantial survival gains in clinical trials for ovarian cancer, offering the most meaningful efficacy signal in decades for the disease. Trial sponsors and investigators characterized the results as a potential pivot point after more than 30 years of limited advance in standard‑of‑care outcomes. Published data and company communications show improvement in overall survival and durability endpoints versus historical controls; investigators note the therapy’s mechanism harnesses adaptive immune responses through tumor‑directed antigen presentation. Sponsors are planning follow‑on studies and regulatory engagement to define registrational pathways and potential combination strategies.